Bausch Health and Salix in Collaboration With Health Organizations Recognize the Second Annual Opioid-Induced Constipation (OIC) Awareness Day
Bausch Health and Salix in Collaboration With Health Organizations Recognize the Second Annual Opioid-Induced Constipation (OIC) Awareness Day
LAVAL, QC / ACCESSWIRE / December 5, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), alongside the U.S. Pain Foundation (USPF), the International Foundation for Gastrointestinal Disorders (IFFGD), and the American Chronic Pain Association (ACPA) have united to recognize today, Thursday, December 5, as the second annual Opioid-Induced Constipation (OIC) Awareness Day. This important day is dedicated to bringing awareness to a commonly-overlooked side effect of opioids. By raising awareness and fostering open conversations, OIC Awareness Day seeks to reduce the stigma surrounding this condition and offer support to the many patients impacted by OIC.
魁北克拉瓦尔 / ACCESSWIRE / 2024年12月5日 / bausch health公司(纽交所:BHC)(tsx:BHC)及其胃肠病(GI)业务Salix药品("Salix"),与美国疼痛基金会(USPF)、国际胃肠疾病基金会(IFFGD)和美国慢性疼痛协会(ACPA)联合宣布,今天,12月5日星期四,被定为第二届阿片类药物引起的便秘(OIC)意识日。这个重要的日子旨在提高人们对阿片类药物常被忽视的副作用的关注。通过提高认识和鼓励开放对话,OIC意识日希望减轻围绕该控件的污名,并为受到OIC影响的许多患者提供支持。
"As an organization dedicated to supporting individuals living with pain conditions, we're proud to participate in this year's OIC Awareness Day," said Kathy Sapp, CEO of ACPA. "By increasing awareness and improving communication between healthcare providers, patients, and caregivers, we can make a meaningful difference for those affected by this commonly occurring condition."
“作为一个致力于支持生活在疼痛控件中的个体的组织,我们自豪地参与今年的OIC意识日,”ACPA首席执行官凯西·萨普表示。“通过提高认识和改善医疗保健提供者、患者和护理人员之间的沟通,我们可以为那些受此常见控件影响的人们带来有意义的改变。”
In 2021, about 21% of adults in the U.S. experienced chronic pain. In 2019, 22% of adults with chronic pain were treated with a prescription opioid in the past three months. Opioids can cause OIC, which is a common side effect of opioid treatment. The annual recognition of OIC Awareness Day provides a platform for patients, caregivers, and healthcare providers to discuss this condition and encourage them to join the #OICAwarenessDay movement.
在2021年,约21%的美国成年人经历了慢性疼痛。在2019年,22%的慢性疼痛成年人在过去三个月内接受了处方阿片类药物的治疗。阿片类药物可能导致OIC,这是一种阿片类药物治疗的常见副作用。每年认识OIC意识日为患者、护理人员和医疗保健提供者提供了一个讨论该控件的平台,并鼓励他们加入#OICAwarenessDay运动。
"We're deeply committed to bringing attention to those affected by OIC on this annual awareness day," said Ceciel Rooker, President and Executive Director of IFFGD. "Empowering patients to speak openly about their symptoms is crucial. It's the first step toward helping to ensure they receive the appropriate treatment, and not suffer in silence."
“我们深切致力于在这个年度意识日关注受到OIC影响的人们,”IFFGD主席兼执行董事塞西尔·鲁克表示。“赋权患者公开谈论他们的症状至关重要。这是确保他们接受适当治疗的第一步,而不是默默承受。”
In honor of the second annual OIC Awareness Day, Salix has refreshed the OICAwarenessDay.com website to offer valuable information and resources for healthcare providers, patients, and caregivers, addressing the causes, symptoms, and management of OIC. Additionally, Salix has partnered with influencers to spread the word online using the hashtag #vOICesOfOIC, launched a content program with Chronicon, a global community for people with chronic illnesses, and shared posts across their social media channels to increase awareness about OIC.
为了纪念第二届OIC意识日,Salix刷新了OICAwarenessDay.com网站,为医疗保健提供者、患者和护理人员提供有关OIC的成因、症状和管理的宝贵信息和资源。此外,Salix与影响者合作,在网上传播信息,使用标签#vOICesOfOIC,与Chronicon(一个全球慢性疾病患者社区)启动内容计划,并在其社交媒体渠道上分享帖子,以提高对OIC的认识。
"We're honored to be a part of OIC Awareness Day for the second year in a row," said Nicole Hemmenway, CEO of USPF. "By continuing to raise awareness about this condition, we aim to educate both healthcare providers and patients about OIC, a commonly overlooked side effect."
"我们很荣幸连续第二年参与OIC宣传日,"美国疼痛基金会的首席执行官Nicole Hemmenway说道。"通过继续提高大家对这种控件的认识,我们的目标是教育医疗保健提供者和患者了解OIC这一常被忽视的副作用。"
For more information on OIC and to learn how you can join the #OICAwarenessDay movement, please visit .
欲了解有关OIC的更多信息,以及如何加入#OICAwarenessDay运动,请访问。
About Bausch Health
关于Bausch Health
Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) is a global diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb Corporation. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors. Our gastroenterology business, Salix Pharmaceuticals, is one of the largest specialty pharmaceutical businesses in the world and has licensed, developed and marketed innovative products for the treatment of gastrointestinal diseases for more than 30 years. For more information about Salix, visit and connect with us on Twitter and LinkedIn. For more information about Bausch Health, visit and connect with us on LinkedIn.
Bausch Health公司(纽交所:BHC)(tsx:BHC)是一家全球多元化的制药公司,通过我们不懈的努力交付更好的医疗保健成果,丰富生活。我们主要在胃肠病学、肝病学、神经病学、皮肤病学、国际药品和眼部健康领域开发、生产和销售一系列产品,通过我们对Bausch + Lomb公司的控股权。我们的目标是成为一个在全球范围内整合的医疗保健公司,受到患者、医疗保健从业者、员工和投资者的信任和重视。我们的胃肠病学业务Salix Pharmaceuticals是世界上最大的专业药物企业之一,已经授权、开发并推出创新产品治疗胃肠疾病超过30年。有关Salix的更多信息,请访问 ,并在Twitter和LinkedIn上关注我们。有关Bausch Health的更多信息,请访问 ,并在LinkedIn上关注我们。
About The U.S. Pain Foundation
关于美国疼痛基金会
The U.S. Pain Foundation is a 501(c)(3) nonprofit with a mission to empower, educate, connect, and advocate for individuals living with chronic illnesses and serious injuries that cause pain, as well as their care partners and clinicians. Through its multiple programs and services, the organization works to elevate the patient voice, increase disease-state education, improve pain care through policy change, expand outreach to underserved and marginalized communities, and provide comprehensive resources to ensure individuals are supported and empowered along their journeys. Learn more at uspainfoundation.org.
美国疼痛基金会是一个501(c)(3)非营利组织,使命是赋权、教育、连接并倡导生活在慢性疾病和严重伤害引起疼痛的人士及其护理伙伴和临床医生。通过其多个项目和服务,该组织旨在提高患者声音,增加疾病状态教育,通过政策变革改善疼痛护理,扩大对服务不足和边缘化社区的宣传,并提供全面资源,以确保个人在其旅程中得到支持和赋权。请访问uspainfoundation.org了解更多信息。
About The International Foundation for Gastrointestinal Disorders
关于国际胃肠疾病基金会
The International Foundation for Gastrointestinal Disorders (IFFGD) is a nonprofit education and research organization dedicated to improving the lives of people affected by chronic gastrointestinal illnesses. Founded in 1991, IFFGD helps improve patient outcomes by enhancing awareness, improving education, and supporting and encouraging research into treatments and cures for chronic digestive disorders.
国际胃肠疾病基金会(IFFGD)是一个非营利教育和研究组织,致力于改善受慢性胃肠疾病影响的人的生活。IFFGD成立于1991年,通过提高意识、改善教育以及支持和鼓励对慢性消化疾病的治疗和治愈进行研究,来帮助改善患者的结果。
About The American Chronic Pain Association
关于美国慢性疼痛协会
The American Chronic Pain Association (ACPA) is a non-profit, 501(c) (3) organization. Our Mission is to facilitate peer support, education, hope, and motivation for individuals living with pain and those treating pain conditions. We strive to raise awareness among the health care community, policymakers, and the public at large about issues of living with physical and emotional pain. Our vision is to motivate those with pain conditions to seek quality care, to optimize healthcare office visits, and to prevent chronic disease.
美国慢性疼痛协会(ACPA)是一个非营利的501(c)(3)组织。我们的使命是为那些生活在疼痛中的个人和治疗疼痛的那些人提供同伴支持、教育、希望和动力。我们努力提高医疗保健社区、政策制定者和公众在忍受身体和情感疼痛问题方面的意识。我们的愿景是激励那些有疼痛病症的人寻求高质量的护理,优化医疗办公室的就诊,预防慢性疾病。
Forward-looking Statements
前瞻性声明
This news release may contain forward-looking statements about the future performance of Bausch Health which may generally be identified by the use of the words "anticipates," "hopes," "expects," "intends," "plans," "should," "could," "would," "may," "believes," "subject to" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Actual results are subject to other risks and uncertainties that relate more broadly to Bausch Health's overall business, including those more fully described in Bausch Health's most recent annual report on Form 10-K and detailed from time to time in Bausch Health's other filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference.
本新闻稿可能包含关于bausch health未来业绩的前瞻性陈述,这些陈述通常可以通过使用“预计”、“希望”、“期望”、“打算”、“计划”、“应该”、“可以”、“将”、“可能”、“相信”、“受制于”等词及其变体或类似表达来识别。这些陈述基于管理层当前的期望和信念,并受到某些风险和不确定性的影响,这些因素可能导致实际结果与前瞻性陈述中描述的情况有实质性差异。实际结果受到与bausch health整体业务更广泛相关的其他风险和不确定性的影响,包括在bausch health最近的10-k表格年报中更全面描述的因素,以及不时详细列出的bausch health在美国证券交易委员会和加拿大证券管理局的其他文件中的因素,这些因素在此通过引用并入。
###
###
Investor Contact: |
Media Contact: |
|
Garen Sarafian |
Katie Savastano |
|
ir@bauschhealth.com |
corporate.communications@bauschhealth.com |
|
877-281-6642 (toll-free) |
(908) 569-3692 |
投资者联系人: |
媒体联系: |
|
加伦·萨拉菲安 |
Katie Savastano |
|
ir@bauschhealth.com |
corporate.communications@bauschhealth.com |
|
877-281-6642(免费电话) |
(908) 569-3692 |
SOURCE: Bausch Health Companies Inc.
来源:bausch health公司。